Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study DOI Open Access
Jesús Rivera‐Esteban, Alba Jiménez-Masip, Sergio Muñoz

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(23), P. 7276 - 7276

Published: Nov. 24, 2023

The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on dysfunction-associated steatotic liver disease (MASLD), hepatic manifestation this syndrome. We aimed to investigate and risk factors MASLD MASLD-associated fibrosis in penitentiary population Catalonia, Spain. A cross-sectional observational study involving eight centers. Participants had at least one disorder were a closed-regimen penitentiary. Individuals with concomitant diseases and/or alcohol consumption excluded. Significant defined as stiffness ≥8 kPa controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, inmates VCTE analyzed. Logistic regression analysis was performed identify predictors significant fibrosis. Out 4338 studied, 1290 (29.7%) disorders, 646 (14.9%) underwent VCTE. mean age 48.0 years (SD 12.1), 89.5% male. 33.9%. found 16.4% 9.4% inmates, In multivariate analysis, T2D, waist circumference, MetS, higher ALT values identified independent for amongst Metabolic disorders including are highly prevalent inmates. seems notably than that general population, underscoring need targeted screening programs therapeutic interventions incarcerated

Language: Английский

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease DOI
Gong Feng, Luca Valenti, Vincent Wai–Sun Wong

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 21(1), P. 46 - 56

Published: Oct. 5, 2023

Language: Английский

Citations

103
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI Open Access
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

et al.

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499

Published: Jan. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Language: Английский

Citations

35
Associations between “Cancer Risk”, “Inflammation” and “Metabolic Syndrome”: A Scoping Review DOI Creative Commons
Elsa Vitale, Alessandro Rizzo, Kazuki Santa

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(5), P. 352 - 352

Published: May 16, 2024

Individuals with metabolic syndrome exhibit simultaneously pro-thrombotic and pro-inflammatory conditions which more probably can lead to cardiovascular diseases progression, type 2 diabetes mellitus, some types of cancer. The present scoping review is aimed at highlighting the association between cancer risk, inflammation, syndrome.

Language: Английский

Citations

21
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets DOI Creative Commons

Yinshuang Chen,

Weipeng Wang, Maria P. Morgan

et al.

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: June 8, 2023

Obesity is a global epidemic and overwhelming evidence indicates that it risk factor for numerous cancers, including hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide. Obesity-associated hepatic tumorigenesis develops from nonalcoholic fatty liver disease (NAFLD), progressing to steatohepatitis (NASH), cirrhosis ultimately HCC. The rising incidence obesity resulting in an increased prevalence NAFLD NASH, subsequently represents increasingly important underlying etiology HCC, particular as other causes HCC such hepatitis infection, are declining due effective treatments vaccines. In this review, we provide comprehensive overview molecular mechanisms cellular signaling pathways involved pathogenesis obesity-associated We summarize preclinical experimental animal models available study features NAFLD/NASH/HCC, non-invasive methods diagnose NAFLD, NASH early-stage Finally, since aggressive tumor with 5-year survival less than 20%, will also discuss novel therapeutic targets ongoing clinical trials.

Language: Английский

Citations

32
Evolving global etiology of hepatocellular carcinoma (HCC): Insights and trends for 2024. DOI
Abraham Koshy

Journal of Clinical and Experimental Hepatology, Journal Year: 2024, Volume and Issue: 15(1), P. 102406 - 102406

Published: Aug. 28, 2024

Language: Английский

Citations

15
Prophylactic treatment with Bacteroides uniformis and Bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet DOI Creative Commons

Jing‐Yuan Xu,

Qiaoyun Xia,

Ting Wu

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Jan. 9, 2024

Hepatic immunity is one of the driving forces for development nonalcoholic steatohepatitis (NASH), and targeting gut microbiota believed to affect hepatic immune constitution. Here, we aimed investigate immunological state in NASH, with a specific emphasis on natural killer (NK) cells. In addition, identify contributing species that target provide new directions support feasibility immunotherapy NASH. A possible NASH population was determined by combination long-term severe fatty liver, metabolic disorders increased serum CK18 detect factors microbiota. induced mice fed high-fat diet verify prophylactic effect functional immunopathology immunologic examined, effector functions NK cells were detected. transcriptome, proteomic, fecal metagenome performed. We observed statistical increase IL-10 (p < 0.001) non-statistical decrease interferon-γ IL-6 population, hinting at possibility tolerance. Fecal Bacteroides uniformis Bifidobacterium bifidum abundant healthy but depleted patients. mice, CD8+T cells, macrophages, dendritic 0.01), inhibited, which identified decreased granzyme B 0.05). improved pathological cues, reduced macrophages also restored cell function, as CD107a Transcriptional translational profiling revealed might restore function through multiple pathways, such reduction inhibitory molecules are novel prophylactics impaired

Language: Английский

Citations

9
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss DOI Open Access

Lalitha Sundararaman,

Divakara Gouda,

Anil Kumar

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1978 - 1978

Published: March 14, 2025

The last two decades have proffered many remarkable choices in managing type 1 and 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), first of which, exenatide, was approved by FDA 2005. Two other major classes drugs also entered market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins 2006, sodium–glucose cotransporter-2 (SGLT-2) with approval occurring 2013. These revolutionized treatment diabetes. Additionally, on horizon, once-weekly basal insulin analog icodec combination semaglutide expected to be available future. Beyond glycemic control, GLP1RAs exhibited benefits conditions associated diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, well neurodegenerative diseases such Alzheimer’s disease. emerging research suggests potential roles certain types cancer, infertility, associative learning. Major cardiovascular events seem lower patients GLP1RAs. While some evidence is robust, findings remain tenuous. It important that clinicians familiar current order provide optimal evidence-based care patients. In not-too-distant future, there may a case prescribe these for outside

Language: Английский

Citations

1
Relationship Between Plasma Aldosterone Concentrations and Non-Alcoholic Fatty Liver Disease Diagnosis in Patients with Hypertension: A Retrospective Cohort Study DOI Creative Commons
Junli Hu, Xintian Cai, Qing Zhu

et al.

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2023, Volume and Issue: Volume 16, P. 1625 - 1636

Published: June 1, 2023

Objective: To investigate the association between plasma aldosterone concentration (PAC) and non-alcoholic fatty liver disease (NAFLD) diagnosis in Chinese hypertensive patients.Methods: We conducted a retrospective study of all patients diagnosed with hypertension January 1, 2010, December 31, 2021.We included 3713 based on criteria for inclusion exclusion.PAC measurement was performed using radioimmunoassay.NAFLD abdominal ultrasonography.Cox regression analysis used to estimate hazard ratios (HRs) 95% confidence intervals (CIs) univariable multivariable models.A generalized additive model identify nonlinear relationships PAC NAFLD diagnosis.Results: A total participants were analysis.Over median follow-up 30 months, 1572 individuals developed new-onset NAFLD.When as continuous variable, risk increased by 1.04 1.24-fold each 1 ng/dL 5 increase PAC, respectively.When considered categorical HR tertile 3 1.71 (95% CI, 1.47-1.98,P < 0.001) compared 1.Overall, there J-shaped relationship NAFLD.By fitting two-piecewise linear recursive algorithm, we identified inflection point at 13 (log-likelihood ratio test, P = 0.005).In adjusted 3, ≥ ng/dL, associated 30% 1.25-1.35,P 0.001). Conclusion:The revealed non-linear elevated levels incidence patients.Notably, significantly when ≥13 ng/dL.Larger, prospective studies are necessary confirm these findings.

Language: Английский

Citations

19
Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990–2019: a decomposition and age–period–cohort analysis DOI
Chunlong Liu, Shijie Zhu, Jian Zhang

et al.

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(12), P. 1222 - 1236

Published: Sept. 4, 2023

Language: Английский

Citations

18
Associations of Relative Fat Mass, a Novel Adiposity Indicator, with Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Data from SPECT-China DOI Creative Commons
Wenqi Shen,

Lingli Cai,

Bin Wang

et al.

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2023, Volume and Issue: Volume 16, P. 2377 - 2387

Published: Aug. 1, 2023

This study aimed to determine the associations of relative fat mass (RFM), a novel adiposity indicator, with prevalence non-alcoholic fatty liver disease (NAFLD) and cardiovascular (CVD) compared discriminative ability RFM other common indicators in general Chinese population.This cross-sectional consisted 11,532 adult participants from SPECT-China (2014-2016). We included six indicators, including body index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height (WHtR), visceral (VAI), lipid accumulation product (LAP). Binary logistic regression analysis was used assess relationship between NAFLD CVD. The receiver operating characteristic (ROC) curve evaluate screen CVD.After adjusting for confounding variables, showed strong association In men, each 1-SD (standard deviation) increase associated more than 3-fold increased risk (OR: 4.33, 95% CI: 3.79-4.93) 66% CVD 1.66, 1.36-2.02); women, per about 4-fold 5.16, 4.62-5.77) 26% 1.26, 1.08-1.47). ROC that WHtR were strongest predictors CVD.RFM significantly prevalent adults might be considered simple tool prediction. Further large longitudinal studies are needed verify our findings.

Language: Английский

Citations

16